Authorized purpose: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Clinical role
PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and quantitative review.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: The proposed Vereos PET/CT system includes an optional Adaptive reconstruction algorithm ("PET AR") to be used as an additional reconstruction method for offline reconstructions. A software patch was released which limits the use of the PET AR reconstruction protocols for the scan type it is compatible with and enables identifying the PET AR reconstructed images with visual identifier to differentiate them from regular PET results.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: The CT subsystem images anatomical cross-sections by computer reconstruction of x-ray transmission data. The PET subsystem images the distribution of PET anatomy-specific radiopharmaceuticals in the patient.
Who uses it?Intended users: Trained physician.
What does the software produce?Output: The clinical value of both technologies increases with the capability to fuse the CT and PET images using Philips fusion viewer Image Fusion software to create a composite image for therapeutic planning. The system also provides tools for quantifying results from the CT and PET images and provides the means for a simplified review of the CT, PET, and fused images.
What is its most important limitation?Key limitation: The proposed Vereos PET/CT system includes an optional Adaptive reconstruction algorithm ("PET AR") to be used as an additional reconstruction method for offline reconstructions. A software patch was released which limits the use of the PET AR reconstruction protocols for the scan type it is compatible with and enables identifying the PET AR reconstructed images with visual identifier to differentiate them from regular PET results.
Clinical takeaway. Clinical role: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing of the system with the PET Adaptive Reconstruction software application: design verification including image quality verification and risk analysis risk mitigation testing, functional and non-functional regression tests, and design validation including internal PET AR image evaluation and external clinical images reviewed by certified board radiologists. It states no clinical study was required; sample clinical images were reviewed by certified radiologists and evaluated to have good image quality. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The CT subsystem images anatomical cross-sections by computer reconstruction of x-ray transmission data. The PET subsystem images the distribution of PET anatomy-specific radiopharmaceuticals in the patient.
Exact FDA submission
Checked 2026-09-19
This replaces the current patient/protocol and supported-study additions with the packet's direct CT transmission and PET radiopharmaceutical input statements.
The clinical value of both technologies increases with the capability to fuse the CT and PET images using Philips fusion viewer Image Fusion software to create a composite image for therapeutic planning. The system also provides tools for quantifying results from the CT and PET images and provides the means for a simplified review of the CT, PET, and fused images.
Exact FDA submission
Checked 2026-09-19
The exact packet supports fused CT/PET images, quantification, simplified review, and therapeutic-planning use; it does not state attenuation-corrected or session-management output in the current wording.
The packet states that CT images provide useful diagnostic information when interpreted by a trained physician; it does not establish the current role list.
The proposed Vereos PET/CT system includes an optional Adaptive reconstruction algorithm ("PET AR") to be used as an additional reconstruction method for offline reconstructions. A software patch was released which limits the use of the PET AR reconstruction protocols for the scan type it is compatible with and enables identifying the PET AR reconstructed images with visual identifier to differentiate them from regular PET results.
Exact FDA submission
Checked 2026-09-19
The packet directly limits PET AR to an optional offline reconstruction and compatible scan types; it does not establish the dossier's broader cleared-workflow or classifier wording.
The exact FDA document reports non-clinical testing of the system with the PET Adaptive Reconstruction software application: design verification including image quality verification and risk analysis risk mitigation testing, functional and non-functional regression tests, and design validation including internal PET AR image evaluation and external clinical images reviewed by certified board radiologists. It states no clinical study was required; sample clinical images were reviewed by certified radiologists and evaluated to have good image quality. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "All the testing described above were used to support the substantial equivalence of the proposed Vereos PET/CT with PET Adaptive Reconstruction software application" … "Design Verification also included image quality verification and risk analysis risk mitigation testing.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-clinical testing of the system with the PET Adaptive Reconstruction software application: design verification including image quality verification and risk analysis risk mitigation testing, functional and non-functional regression tests, and design validation including internal PET AR image evaluation and external clinical images reviewed by certified board radiologists. It states no clinical study was required; sample clinical images were reviewed by certified radiologists and evaluated to have good image quality. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "All the testing described above were used to support the substantial equivalence of the proposed Vereos PET/CT with PET Adaptive Reconstruction software application" … "Design Verification also included image quality verification and risk analysis risk mitigation testing.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K211764 FDA performance package for Vereos PET/CT
DesignManufacturer nonclinical PET/CT, PET Adaptive Reconstruction, software, regression, and simulated-use validation
PopulationWhole-body, cardiac, brain, lung, gastrointestinal, bone, lymphatic, and organ PET/CT workflows across oncology, cardiology, and neurology
Scopeexact submission
Tested versionVereos PET/CT
IndependenceSponsor or vendor study
K211764
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211764 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: The CT subsystem images anatomical cross-sections by computer reconstruction of x-ray transmission data. The PET subsystem images the distribution of PET anatomy-specific radiopharmaceuticals in the patient.
Scope: Exact FDA submission. This replaces the current patient/protocol and supported-study additions with the packet's direct CT transmission and PET radiopharmaceutical input statements.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
Scope: Product family. Current vendor materials are product-family evidence for K211764; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Installed PET/CT scanner, console, reconstruction options, and supported clinical or radiotherapy interfaces.
Scope: Product family. Current vendor materials are product-family evidence for K211764; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: The clinical value of both technologies increases with the capability to fuse the CT and PET images using Philips fusion viewer Image Fusion software to create a composite image for therapeutic planning. The system also provides tools for quantifying results from the CT and PET images and provides the means for a simplified review of the CT, PET, and fused images.
Scope: Exact FDA submission. The exact packet supports fused CT/PET images, quantification, simplified review, and therapeutic-planning use; it does not state attenuation-corrected or session-management output in the current wording.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The clinical value of both technologies increases with the capability to fuse the CT and PET images using Philips fusion viewer Image Fusion software to create a composite image for therapeutic planning. The system also provides tools for quantifying results from the CT and PET images and provides the means for a simplified review of the CT, PET, and fused images.
Scope: Exact FDA submission. The exact packet supports fused CT/PET images, quantification, simplified review, and therapeutic-planning use; it does not state attenuation-corrected or session-management output in the current wording.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Installed PET/CT scanner, console, reconstruction options, and supported clinical or radiotherapy interfaces.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211764; confirm the exact cleared version, enabled options, deployment, and local compatibility.
PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211764; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.
Only qualified nuclear medicine physicians, radiologists, technologists, and other trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared radiopharmaceuticals, scan ranges, reconstruction options, and patient or planning workflows; PET Adaptive Reconstruction is a reconstruction option and is not evidence of an independent diagnostic classifier.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211764; confirm the exact cleared version, enabled options, deployment, and local compatibility.
PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only cleared radiopharmaceuticals, scan ranges, reconstruction options, and patient or planning workflows; PET Adaptive Reconstruction is a reconstruction option and is not evidence of an independent diagnostic classifier.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only cleared radiopharmaceuticals, scan ranges, reconstruction options, and patient or planning workflows; PET Adaptive Reconstruction is a reconstruction option and is not evidence of an independent diagnostic classifier.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact packet identifies PET and X-ray CT; it does not establish the dossier's SPECT wording. Controlled directory display reconciled from exact FDA wording: Positron Emission Tomography (PET) and X-ray Computed Tomography (CT) systems. -> PET/SPECT/Nuclear Medicine.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
8Screened PubMed leads
3Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 8 PubMed and 3 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 8 PubMed and 3 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.